The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical TrialHagen Schwenzer, Sarah P. Blagden, Gareth L. Bond et al.|Clinical Cancer Research|2021Cited by 44
Abstract 1855: NUC-1031 overcomes resistance associated with gemcitabine in cancer patientsJennifer Bré, David J. Harrison, In Hwa Um et al.|Cancer Research|2018Cited by 2
Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 studySarah P. Blagden, Elizabeth Ruth Plummer, Aglaia Skolariki et al.|Molecular Cancer Therapeutics|2023Cited by 1
Abstract 6222: Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapyAlison L. Dickson, David J. Harrison, In Hwa Um et al.|Cancer Research|2024Cited by 1
Table S2 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical TrialHagen Schwenzer, Sarah P. Blagden, Michaela Serpi et al.|Unknown|2024Cited by 0